(2S,4R)-4-(2-Aminoacetamido)-N-[(1R)-2-(4-flourophenyl)-1-(3-quinolylcarbamoyl)ethyl]-2-pyrrolidinecarboxamide | 1105971-84-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-4-(2-Aminoacetamido)-N-[(1R)-2-(4-flourophenyl)-1-(3-quinolylcarbamoyl)ethyl]-2-pyrrolidinecarboxamide
• 英文别名: (2S,4R)-4-[(2-aminoacetyl)amino]-N-[(2R)-3-(4-fluorophenyl)-1-oxo-1-(quinolin-3-ylamino)propan-2-yl]pyrrolidine-2-carboxamide
• CAS: 1105971-84-3
• 化学式: C₂₅H₂₇FN₆O₃
• 分子量: 478.526
• InChiKey: SXNZUWQTTMIIOF-BAGYTPMASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  138
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  BOC-DL-4-氟苯丙氨酸 生成 (2S,4R)-4-(2-Aminoacetamido)-N-[(1R)-2-(4-flourophenyl)-1-(3-quinolylcarbamoyl)ethyl]-2-pyrrolidinecarboxamide
  参考文献：
  名称：

  Efflux pump inhibitors

  摘要：

  描述了具有外流泵抑制剂活性的化合物。还描述了使用这种外流泵抑制剂化合物的方法以及包括这种化合物的药物组合物。

  公开号：

  US06399629B1

文献信息

• Antibacterial Compounds
  申请人：VICTORIA LINK LIMITED

  公开号：US20190328687A1

  公开（公告）日：2019-10-31

  The present invention relates to salicylamide compounds and compositions thereof effective in targeting growth of bacteria. The compounds and compositions of the present invention are particularly useful in, for example, the prevention or treatment of bacterial infection and the prevention, reduction or elimination of biofilm formation.
• METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE
  申请人：Rhode Island Hospital

  公开号：US20200268693A1

  公开（公告）日：2020-08-27

  Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated with H. Pylori in a subject infected by H. Pylori , the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
• TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE
  申请人：UNION therapeutics A/S

  公开号：US20210137948A1

  公开（公告）日：2021-05-13

  The present invention relates to halogenated salicylanilides, such as closantel, rafoxanide, oxyclozanide, niclosamide, or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of an infection caused by N. gonococcus bacteria in a subject, such as treatment of gonococcal conjunctivitis or anorectal gonorrhoea.
• US6399629B1
  申请人：——

  公开号：US6399629B1

  公开（公告）日：2002-06-04